Sabra Health Care REIT, Inc. to Attend Citi’s 2024 Global Property CEO Conference and the 2024 NIC Spring Conference
Sabra Health Care REIT, Inc. to Attend Citi’s 2024 Global Property CEO Conference and the 2024 NIC Spring Conference
Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that Rick Matros, the company’s Chair and Chief Executive Officer, Michael Costa, the company’s Chief Financial Officer, and Lukas Hartwich, the company’s Senior Vice President of Finance, will attend Citi’s 2024 Global Property CEO Conference on March 4-6, 2024, at The Diplomat Beach Resort in Hollywood, Florida.
Additionally, Talya Nevo-Hacohen, the company’s Chief Investment Officer, Darrin Smith, the company’s Executive Vice President of Investments, and other members of the company, will attend the 2024 NIC Spring Conference on March 5-7, 2024, at the Omni Dallas Hotel in Dallas, Texas.
About Sabra
Sabra Health Care REIT, Inc., a Maryland corporation, operates as a self-administered, self-managed real estate investment trust (a “REIT”) that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada.
Investor & Media Inquiries: 1-888-393-8248 or investorinquiries@sabrahealth.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220456433/en/
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact